Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC
Interim ASCO Data Show Improvement in PD-L1 Expressors, All-Comers
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.